Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dispenzieri, Angela, Krishnan, Amrita, Arendt, Bonnie, Blackwell, Beth, Wallace, Paul K., Dasari, Surendra, Vogl, Dan T., Efebera, Yvonne, Fei, Mingwei, Geller, Nancy, Giralt, Sergio, Hahn, Theresa, Howard, Alan, Kohlhagen, Mindy, Landau, Heather, Hari, Parameswaran, Pasquini, Marcelo C., Qazilbash, Muzaffar H., McCarthy, Philip, Shah, Nina, Vesole, David H., Stadtmauer, Edward, Murray, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831597/
https://www.ncbi.nlm.nih.gov/pubmed/35145071
http://dx.doi.org/10.1038/s41408-022-00624-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831597/
https://www.ncbi.nlm.nih.gov/pubmed/35145071
http://dx.doi.org/10.1038/s41408-022-00624-6

Ejemplares similares